Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
NCT03627403Phase 2Terminated
- Sponsor
- University of Utah
- Start
- May 2019
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in myelofibrosis (MF), sponsored by University of Utah. Started May 2019; status: terminated.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03627403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627403.